Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of data fro
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … prior experience in cholestatic disease and rare disease drugdevelopment would be an advantage. 5-10 years’ …
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … industry with excellent knowledge of multiple Phases of drugdevelopment. Ideally, experience working with large …
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life-changing RNA therapies to meet the unmet … outcome-driven, value-creating activities early in the drugdevelopment process Market and Competitive Intelligence: …
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr.